Can't access Anktiva for bladder cancer? Explore FDA-approved alternatives like Pembrolizumab, Adstiladrin, Valrubicin, and off-label treatment options.
If you've been prescribed Anktiva (nogapendekin alfa inbakicept-pmln) but can't access it — whether due to the BCG shortage, insurance barriers, or availability issues — you're understandably worried. BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) is a serious condition, and time matters.
The good news is that there are other FDA-approved and evidence-based treatment options available. In this guide, we'll walk through the alternatives to Anktiva so you and your doctor can make an informed decision about your care.
There are several common reasons patients can't access Anktiva in 2026:
Whatever the reason, it's important to discuss alternatives with your urologic oncologist rather than delaying treatment. For more on why Anktiva is hard to find, see our detailed explainer.
Pembrolizumab, sold under the brand name Keytruda, is a systemic immunotherapy drug (checkpoint inhibitor) approved for BCG-unresponsive NMIBC with CIS. It works differently from Anktiva — instead of supercharging immune cells directly, it removes the "brakes" that cancer cells use to hide from the immune system.
Key facts about Pembrolizumab for bladder cancer:
Pembrolizumab is widely available and has established insurance coverage as a well-known cancer immunotherapy.
Nadofaragene firadenovec, marketed as Adstiladrin, is an intravesical gene therapy approved for BCG-unresponsive NMIBC with CIS. It delivers a gene that instructs bladder cells to produce interferon alfa-2b, which activates the local immune response against cancer.
Key facts about Adstiladrin:
Valrubicin, sold as Valstar, is an intravesical chemotherapy drug that has been available much longer than the newer immunotherapies. It's approved specifically for BCG-refractory CIS in patients for whom cystectomy is not an option.
Key facts about Valrubicin:
The combination of Gemcitabine and Docetaxel is not FDA-approved for this specific indication, but it is widely used off-label by urologists for BCG-unresponsive NMIBC. Both drugs are common chemotherapy agents available at most treatment centers.
Key facts:
Here's a quick comparison to help you understand your options:
Every patient's situation is different. The best alternative depends on your specific cancer characteristics, overall health, whether you're a candidate for cystectomy, and what's available at your treatment center.
Radical cystectomy (surgical removal of the bladder) remains the standard treatment for patients with BCG-unresponsive NMIBC who don't respond to other therapies. While it's a major surgery with significant lifestyle changes, it offers the most definitive cancer treatment.
One important note from the Anktiva prescribing information: delaying cystectomy in the presence of persistent CIS may increase the risk of developing metastatic bladder cancer. If you can't access Anktiva or other alternatives, discuss the timing of cystectomy with your surgical team.
Don't make any changes to your treatment plan on your own. Your urologic oncologist can help you:
If you're still hoping to access Anktiva, continue working with the MedFinder platform and the ImmunityBio CARE program (1-877-ANKTIVA) while exploring alternatives.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
